Literature DB >> 2729394

Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester.

G Koren1, M Bologa, D Long, Y Feldman, N H Shear.   

Abstract

We assessed the perception of teratogenic risk by 80 women attending an antenatal consultation service for drug, chemical, and radiation exposure. Women exposed to agents not known to be teratogenic assigned themselves a risk of 24% +/- 2.8% for major malformation before the relevant medical literature was delivered to them and 14.5% +/- 3% thereafter. These women accurately estimated the risk for major malformation in the general population (5.6% +/- 1.3%). The tendency to terminate pregnancy when exposed to a nonteratogen significantly decreased after the consultation. Eleven patients exposed to drugs known to be teratogenic assigned a risk of 36.2% +/- 11.7% before the interview and did not change their perception thereafter (36.7% +/- 15.8%). Similarly, their tendency to continue or terminate pregnancy did not change; three of them eventually chose to terminate the pregnancy. Advising women about their teratogenic risk early in pregnancy may prevent unjustified termination of many pregnancies and may help to inform women exposed to proven teratogens about the known risk.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2729394     DOI: 10.1016/0002-9378(89)90186-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  28 in total

1.  First trimester exposure to cefuroxime: a prospective cohort study.

Authors:  M Berkovitch; I Segal-Socher; R Greenberg; M Bulkowshtein; J Arnon; P Merlob; A Or-Noy
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  Pharmacotherapy and pregnancy: Highlights from the first International Conference for Individualized Pharmacotherapy in Pregnancy.

Authors:  David M Haas; Jamie L Renbarger; Scott Denne; Mahmoud S Ahmed; Thomas Easterling; Karen Feibus; Eric M Meslin; Gideon Koren; Anne Zajicek; Wayne R Snodgrass; David A Flockhart
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

3.  Investigating drug use in pregnancy. Methodological problems and perspectives.

Authors:  L T De Jong-van den Berg; P B Van den Berg; F M Haaijer-Ruskamp; M N Dukes; H Wesseling
Journal:  Pharm Weekbl Sci       Date:  1991-02-22

4.  Drug use in pregnancy--physicians' evaluation of quality and clinical impact of drug information centres.

Authors:  Sofia Kristina Frost Widnes; Jan Schjøtt
Journal:  Eur J Clin Pharmacol       Date:  2008-12-04       Impact factor: 2.953

Review 5.  Therapeutic drug monitoring of antithyroid drugs in pregnancy: the knowledge gaps.

Authors:  Gideon Koren; Offie Soldin
Journal:  Ther Drug Monit       Date:  2006-02       Impact factor: 3.681

6.  Lead exposure among mothers and their newborns in Toronto.

Authors:  G Koren; N Chang; R Gonen; J Klein; L Weiner; H Demshar; S Pizzolato; I Radde; J Shime
Journal:  CMAJ       Date:  1990-06-01       Impact factor: 8.262

7.  Counselling pregnant women at the crossroads of Europe and Asia: effect of Teratology Information Service in Turkey.

Authors:  Yusuf Cem Kaplan; Barış Karadaş; Gözde Küçüksolak; Bartu Ediz; Ömer Demir; Kaan Sozmen; Hedvig Nordeng
Journal:  Int J Clin Pharm       Date:  2017-06-19

8.  Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs.

Authors:  Kathleen Uhl; Dianne L Kennedy; Sandra L Kweder
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

9.  Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study.

Authors:  R Loebstein; A Addis; E Ho; R Andreou; S Sage; A E Donnenfeld; B Schick; M Bonati; M Moretti; A Lalkin; A Pastuszak; G Koren
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Teratogenic risk perception and confidence in use of medicines in pairs of pregnant women and general practitioners based on patient information leaflets.

Authors:  Sofia Frost Widnes; Jan Schjøtt; Geir Egil Eide; Anne Gerd Granas
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.